Divi's Laboratories Ltd
NSE:DIVISLAB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 367.85
6 256.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Divi's Laboratories Ltd
Divi's Laboratories Ltd
Net Income (Common)
Divi's Laboratories Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Net Income (Common)
₹16.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Suven Life Sciences Ltd
NSE:SUVEN
|
Net Income (Common)
-₹1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Net Income (Common)
-₹1.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Net Income (Common)
₹4.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Vimta Labs Ltd
NSE:VIMTALABS
|
Net Income (Common)
₹410.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Net Income (Common)
₹943.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Divi's Laboratories Ltd
Glance View
Divi's Laboratories Ltd. has carved an enviable niche for itself in the global pharmaceutical industry, with its origins tracing back to 1990 in Hyderabad, India. With a steadfast focus on research and development, the company stands as a formidable force in the Active Pharmaceutical Ingredients (APIs) and Intermediates manufacturing sector. Its strategy hinges on two complementary business segments: generic APIs and custom synthesis of APIs and intermediates. By catering to a broad spectrum of therapeutic areas, from cardiovascular ailments to pain management, Divi's capitalizes on economies of scale and technological innovation to produce cost-effective, high-quality pharmaceutical products. This strategy not only aligns with the company’s expertise in process development and chemical synthesis but also positions it as a key supplier to major pharmaceutical companies worldwide, providing a significant portion of their API requirements. The crux of Divi's financial engine lies in its custom synthesis segment, where it forms strategic alliances with global pharmaceutical giants, offering end-to-end solutions from drug discovery to commercialization. This vertical is fueled by long-term contracts that bolster the company’s revenue visibility and profitability. Meanwhile, the generic APIs segment benefits from the rising global demand for affordable healthcare solutions, particularly in emerging markets. Divi’s Laboratories leverages its state-of-the-art manufacturing facilities, which are compliant with international regulatory standards, to ensure efficient production cycles and maintain a consistent supply chain. Through its blend of innovative R&D, a robust manufacturing backbone, and strategic partnerships, Divi's Laboratories adeptly navigates the complexities of the pharmaceutical industry, making it a stalwart in the sector's supply chain ecosystem.
See Also
What is Divi's Laboratories Ltd's Net Income (Common)?
Net Income (Common)
16.7B
INR
Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Net Income (Common) amounts to 16.7B INR.
What is Divi's Laboratories Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
4%
Over the last year, the Net Income (Common) growth was 13%. The average annual Net Income (Common) growth rates for Divi's Laboratories Ltd have been -7% over the past three years , 4% over the past five years .
You don't have any saved screeners yet
